SpringWorks Therapeutics Inc.

07/01/2024 | Press release | Distributed by Public on 07/01/2024 05:59

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.